Colorectal cancer

Introduction 344 Treatment approaches to colorectal cancer 346 Care of the patient with a stoma 350 Nursing management issues 354 • Colorectal cancer is the third commonest cancer in UK (fourth worldwide) with over 34,000 UK cases diagnosed annually. • It affects men and women almost equally....

2018 ◽  
Vol 11 (3) ◽  
pp. 791-796 ◽  
Author(s):  
Tagore Sunkara ◽  
Megan E Caughey ◽  
Priyanka Makkar ◽  
Febin John ◽  
Vinaya Gaduputi

Overall, colorectal cancer is the third most commonly diagnosed cancer in both men and women, meaning that it is one of the more widely recognized preventable cancers. Instances of colorectal malignancies though are overwhelmingly attributable to adenocarcinoma. Colorectal cancers with components of squamous cell carcinoma represent a statistical anomaly. Here, we present the case of a 50-year-old male, who complained of abdominal pain and weight loss over a 3-month period of time. Biopsies from a colonoscopy ultimately revealed that this patient’s colon cancer consisted of both adenocarcinoma and squamous cell carcinoma, representing a truly exceptional pathology finding in a patient diagnosed with a colorectal cancer.


2019 ◽  
Vol 10 (10) ◽  
pp. 659-669
Author(s):  
Aliasgar Shahiwala ◽  
Samar Salam Qawoogha ◽  
Murtaza M Tambuwala

Colorectal cancer is considered the third most frequent malignant neoplasm occurring in both men and women worldwide. Most approaches that have been used to fight and treat this type of malignancy are either invasive or nonselective. Noninvasive therapy using oral route can increase patient compliance and reduce treatment costs. Innovative measures such as use of nanotechnology and theranostic systems have been initiated in the oral therapy, which has been proven to be greatly advantageous in decreasing side effects, improving detection and diagnoses. This manuscript investigates recent innovative and novel therapeutic approaches through oral route and potential targets in the treatment of colorectal cancer.


2005 ◽  
Vol 3 (4) ◽  
pp. 468 ◽  

Colorectal cancer is the third most frequently diagnosed cancer in men and women in the United States, and in 2005, an estimated 104,950 new cases of colon cancer will occur. Despite these statistics, mortality from colon cancer has decreased over the past 30 years, possibly because of earlier diagnosis through screening and better treatment modalities. The NCCN guidelines summarize the management of colon cancer, from disease presentation through management of recurrent disease and patient surveillance. For the most recent version of the guidelines, please visit NCCN.org


2004 ◽  
Vol 18 (2) ◽  
pp. 93-99 ◽  
Author(s):  
Desmond Leddin ◽  
Richard Hunt ◽  
Malcolm Champion ◽  
Alan Cockeram ◽  
Nigel Flook ◽  
...  

Colorectal cancer is the third most prevalent cancer affecting both men and women in Canada. Many of these cancers are preventable, and the Canadian Association of Gastroenterology (CAG) and the Canadian Digestive Health Foundation (CDHF) strongly support the establishment of screening programs for colorectal cancer. These guidelines discuss a number of screening options, listing the advantages and disadvantages of each. Ultimately, the test that is used for screening should be determined by patient preference, current evidence and local resources.


2021 ◽  
Vol 6 (1) ◽  
pp. 1300-1306
Author(s):  
Vandra Bina Riyanda ◽  
Reno Rudiman ◽  
Nurhayat Usman

Background: According to the American Cancer Society, Colorectal Cancer (CRC) is the third leading cause of cancer death in men and women in the United States. In Indonesia, CRC ranks as the third most common malignancy in both men and women. Programmed death-ligand 1(PD-L1) is a trans-membrane receptor ligand and negative regulatory signal for T cells that is elevated in several tumors including CRC and binds to programmed death 1 (PD-1) on T cells, B cells, dendritic cells and natural killer T cells. PD-L1 expression was found in tumor cells and tumor cells that infiltrate immune cells in several malignancies, including CRC. Methods: This study is a comparative analytic cross sectional study with consecutive sampling method. This study was conducted at Hasan Sadikin Hospital, Bandung from September to October 2021. Further statistical analysis was done SPSS version 25.0 for Windows (SPSS Inc., Chicago, Ill., USA). Results: The total sample in this study was 50 subjects with colorectal cancer patients at RSHS. The number of CRC patients who expressed PD-L1 were 23 (46%) and 27 subjects (54%). The majority of cancer patient survival 2 Years was 38 subjects (76.0%) and survivors of more than 2 years was 12 subjects (24.0%). Conclusion: There is no significant relationship between PD-L1 and survival rates in CRC patients.


2020 ◽  
Vol 27 (17) ◽  
pp. 2779-2791 ◽  
Author(s):  
Anna Nappi ◽  
Guglielmo Nasti ◽  
Carmela Romano ◽  
Massimiliano Berretta ◽  
Alessandro Ottaiano

: Colorectal cancer represents the third most frequently occurring cancer worldwide. In the last decade, the survival of patients affected by metastatic colorectal cancer (mCRC) has improved through the introduction of biological drugs. However, in this new and dynamic therapeutic context, research about prognostic and predictive factors is important to guide the oncologists to effective therapies as well as to improve the understanding of colorectal cancer biology. Their identification is an intensive area of research and our future goal will be to depict tumour-specific "molecular signatures" in order to predict the clinical course of the disease and the best treatments. : In this report, we describe clinical, pathological and molecular biomarkers that can play a role as prognostic or predictive factors in mCRC.


2021 ◽  
Vol 147 (5) ◽  
pp. 1407-1419
Author(s):  
Manuela Limam ◽  
Katarina Luise Matthes ◽  
Giulia Pestoni ◽  
Eleftheria Michalopoulou ◽  
Leonhard Held ◽  
...  

Abstract Background Colorectal cancer (CRC) is among the three most common incident cancers and causes of cancer death in Switzerland for both men and women. To promote aspects of gender medicine, we examined differences in treatment decision and survival by sex in CRC patients diagnosed 2000 and 2001 in the canton of Zurich, Switzerland. Methods Characteristics assessed of 1076 CRC patients were sex, tumor subsite, age at diagnosis, tumor stage, primary treatment option and comorbidity rated by the Charlson Comorbidity Index (CCI). Missing data for stage and comorbidities were completed using multivariate imputation by chained equations. We estimated the probability of receiving surgery versus another primary treatment using multivariable binomial logistic regression models. Univariable and multivariable Cox proportional hazards regression models were used for survival analysis. Results Females were older at diagnosis and had less comorbidities than men. There was no difference with respect to treatment decisions between men and women. The probability of receiving a primary treatment other than surgery was nearly twice as high in patients with the highest comorbidity index, CCI 2+, compared with patients without comorbidities. This effect was significantly stronger in women than in men (p-interaction = 0.010). Survival decreased with higher CCI, tumor stage and age in all CRC patients. Sex had no impact on survival. Conclusion The probability of receiving any primary treatment and survival were independent of sex. However, female CRC patients with the highest CCI appeared more likely to receive other therapy than surgery compared to their male counterparts.


Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3395
Author(s):  
Maria Radanova ◽  
Galya Mihaylova ◽  
Neshe Nazifova-Tasinova ◽  
Mariya Levkova ◽  
Oskan Tasinov ◽  
...  

Colorectal cancer (CRC) is ranked as the second most commonly diagnosed disease in females and the third in males worldwide. Therefore, the finding of new more reliable biomarkers for early diagnosis, for prediction of metastasis, and resistance to conventional therapies is an important challenge in overcoming the disease. The current review presents circular RNAs (circRNAs) with their unique features as potential prognostic and diagnostic biomarkers in CRC. The review highlights the mechanism of action and the role of circRNAs with oncogenic functions in the CRC as well as the association between their expression and clinicopathological characteristics of CRC patients. The comprehension of the role of oncogenic circRNAs in CRC pathogenesis is growing rapidly and the next step is using them as suitable new drug targets in the personalized treatment of CRC patients.


Sign in / Sign up

Export Citation Format

Share Document